Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | MC4R | P32245 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | MALT1 | Q9UDY8 | 11/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 3/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31377061 | 1.00 | POLB (0.59) | POLBMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL31377060 | 0.90 | POLB (0.46) | POLBMAPTSMN1; SMN2MALT1KDM4E | |
| SCHEMBL31007079 | 0.90 | POLB (0.46) | POLBMAPTSMN1; SMN2MALT1KDM4E | |
| SCHEMBL30097595 | 0.89 | MALT1 (0.45) | POLBMAPTSMN1; SMN2MALT1KDM4E | |
| SCHEMBL30097896 | 0.87 | POLB (0.62) | POLBMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL27171661 | 0.87 | POLB (0.62) | POLBMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL30861257 | 0.86 | POLB (0.60) | POLBMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL27171662 | 0.86 | POLB (0.60) | POLBMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL21605010 | 0.85 | MAPT (0.59) | POLBMAPTSMN1; SMN2MEN1KMT2A | |
| SCHEMBL21605033 | 0.85 | MAPT (0.56) | POLBMAPTSMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240425480-A1 | NOVEL PYRIDINE DERIVATIVE COMPOUND AS RON INHIBITOR | LG CHEM, LTD. (KR) | 2024-12-26 | — | — | US | disclosed |
| US-20240317739-A1 | NOVEL UREA DERIVATIVE COMPOUND AS RON INHIBITOR | LG CHEM, LTD. (KR) | 2024-09-26 | — | — | US | disclosed |
| WO-2024134514-A1 | NOVEL COMPOUND AS RON INHIBITOR | 주식회사 엘지화학 | 2024-06-27 | — | — | WO | disclosed |
| EP-4349825-A1 | NOVEL PYRIDINE DERIVATIVE COMPOUND AS RON INHIBITOR | LG Chem, Ltd. (KR) | 2024-04-10 | — | — | EP | disclosed |
| EP-4339196-A1 | NOVEL UREA DERIVATIVE COMPOUND AS RON INHIBITOR | LG Chem, Ltd. (KR) | 2024-03-20 | — | — | EP | disclosed |
| CN-117500804-A | Novel urea derivative compounds as RON inhibitors | 株式会社LG化学 | 2024-02-02 | — | — | CN | disclosed |
| CN-117396468-A | Novel pyridine derivative compounds as RON inhibitors | 株式会社LG化学 | 2024-01-12 | — | — | CN | disclosed |
| EP-3807266-B1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-25 | — | — | EP | disclosed |
| EP-3807266-B1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2023-10-25 | — | — | EP | disclosed |
| CN-112585128-B | Pyrazole derivatives as MALT1 inhibitors | 詹森药业有限公司 | 2023-02-21 | — | — | CN | disclosed |
| WO-2019243964-A1 | PYRAZOLE DERIVATIVES AS MALT1 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2019-12-26 | — | — | WO | disclosed |
| EP-2462139-B1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2015-01-14 | — | — | EP | disclosed |
| EP-2462139-B1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2015-01-14 | — | — | EP | disclosed |
| US-8399451-B2 | Heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399451-B2 | Heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-19 | — | — | US | disclosed |
| US-8399451-B2 | Heterocyclic compounds | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-03-19 | — | — | US | disclosed |
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-04 | — | — | US | disclosed |
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-04 | — | — | US | disclosed |
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2011-08-04 | — | — | US | disclosed |
| WO-2011017578-A1 | SPHINGOSINE-1-PHOSPHATE RECEPTOR AGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190255-A1 | HETEROCYCLIC COMPOUNDS | S1PR1, S1PR3, S1PR5 | POLB 3979/4885MAPT 4760/4885SMN1; SMN2 1771/4885 |
| US-20240425480-A1 | NOVEL PYRIDINE DERIVATIVE COMPOUND AS RON INHIBITOR | RET, MST1R, ROS1 | POLB 4572/4885MAPT 4286/4885SMN1; SMN2 4129/4885 |
| US-20240317739-A1 | NOVEL UREA DERIVATIVE COMPOUND AS RON INHIBITOR | CDKN1A, RET, UBTF | POLB 3957/4885MAPT 2721/4885SMN1; SMN2 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.